.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,679,534

« Back to Dashboard

Details for Patent: 8,679,534

Title:HMG-CoA reductase inhibitor extended release formulation
Abstract: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (T.sub.max) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.
Inventor(s): Chen; Chih-Ming (Davie, FL), Chou; Joseph (Coral Springs, FL), Wong; David (Hollywood, FL)
Assignee: Andrx Labs, LLC (Davie, FL)
Filing Date:Feb 16, 2006
Application Number:11/355,335
Claims:1. A method for reducing serum cholesterol levels in humans comprising orally administering to a human on a once a day basis a controlled release lovastatin tablet comprising 10 to 80 mg of lovastatin and formulated with a core comprising the lovastatin and a water swellable polymer and a coating surrounding the core wherein the coating comprises a water insoluble polymer and a pH sensitive polymer that dissolves at a pH above 3 to release less than 20% of the lovastatin after 2 hours of in vitro testing and between 20% and 70% of the lovastatin after 5 hours of in vitro testing wherein the in vitro testing is conducted using a USP XXII, Type II dissolution apparatus in 2% sodium lauryl sulfate, pH 7.0 NaH.sub.2PO.sub.4 buffer at 37.degree. C. and 50 rpms, so that a mean time to maximum plasma concentration of lovastatin after a single dose administration in the morning without food is at least about 12 hours and the ratio of AUC.sub.0-48hr of lovastatin for the controlled release dosage form to AUC.sub.0-48hr of lovastatin for an immediate release oral lovastatin tablet is greater than unity following the single dose administration of the controlled release tablet and immediate release tablet.

2. The method of claim 1 wherein pH sensitive polymer dissolves at a pH above 5.5.

3. The method of claim 1 wherein the controlled release tablet is an osmotic tablet.

4. A method for reducing serum cholesterol levels in humans comprising orally administering to a human on a once a day basis a controlled release lovastatin tablet comprising 10 to 80 mg of lovastatin and formulated with a core comprising the lovastatin and a water swellable polymer and a coating surrounding the core wherein the coating comprises a water insoluble polymer and a pH sensitive polymer that dissolves at a pH above 3, wherein: (a) the tablet releases 0 to about 25% of the lovastatin after 2 hours of in vitro testing, about 40 to about 85% of the lovastatin after 6 hours of in vitro testing and not less than about 75% of the lovastatin after 16 hours of in vitro testing wherein the in vitro testing is conducted using a USP XXII, Type II dissolution apparatus in 2% sodium lauryl sulfate, pH 7.0 NaH.sub.2PO.sub.4 buffer at 37.degree. C. and 50 rpms; (b) a mean time to maximum plasma concentration of lovastatin of about 10 to about 32 hours is obtained after a single dose administration; (c) a mean time to maximum plasma concentration of lovastatin acid of about 13 to about 20.9 hours is obtained after a single dose administration; and (d) a ratio of AUC.sub.0-48hr of lovastatin for the controlled release tablet to AUC.sub.0-48hr of lovastatin for an immediate release oral lovastatin tablet is greater than unity and the ratio of AUC.sub.0-48hr of lovastatin acid for the controlled release tablet to AUC.sub.0-48hr of lovastatin acid for an immediate release oral lovastatin tablet is greater than unity following the single dose administration of the controlled release tablet and immediate release tablet.

5. The method of claim 4 wherein the controlled release tablet releases 0 to about 20% of the lovastatin after 2 hours of in vitro testing, about 50 to about 80% of the lovastatin after 6 hours of in vitro testing and not less than about 80% of the lovastatin after 16 hours of in vitro testing wherein the in vitro testing is conducted using a USP XXII, Type II dissolution apparatus in 2% sodium lauryl sulfate, pH 7.0 NaH.sub.2PO.sub.4 buffer at 37.degree. C. and 50 rpms.

6. The method of claim 4 wherein the pH sensitive polymer dissolves at a pH above 5.5.

7. The method of claim 4 wherein the controlled release tablet is an osmotic tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc